<DOC>
	<DOCNO>NCT02039245</DOCNO>
	<brief_summary>The purpose study evaluate multiple dose pharmacokinetics 2 Canagliflozin/extended release Metformin ( CANA/MET XR ) fix dose combination tablet ( 150 mg/1,000 mg ) follow once-daily oral dose healthy participant .</brief_summary>
	<brief_title>Multiple Dose Pharmacokinetics Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination</brief_title>
	<detailed_description>This open-label ( physicians participant know identity assign treatment ) , multiple-dose , single-center , pharmacokinetic study fix dose combination ( FDC ) 150 mg/1,000 mg Canagliflozin/extended release Metformin ( CANA/MET XR ) tablet . The study consist 3 phase : Screening Phase approximately 3 week , Open-Label Treatment Phase , ( participant confine study center 11 day ) , Follow-up Phase 10 day . The total duration study 42 day participant . During Open-Label Treatment Phase , approximately 12 healthy adult participant receive single oral dose 2 CANA/MET XR tablet daily 7 day provide dinner . Participants require fast end lunch dinner ( period least 6.5 hour ) Days 1 7 .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Must sign inform consent document indicate understand purpose study procedure Must body mass index ( BMI ) 18 30 kg/m² , inclusive Must body weight less 50 kg Must blood pressure 90 140 mmHg inclusive , systolic , high 90 mmHg diastolic screen Must normal renal function evidence kidney damage ( include abnormality blood urine test ) History current clinically significant medical illness Use systemic prescription nonprescription medication ( include vitamin herbal supplement ) Known allergy canagliflozin metformin excipients formulation Known allergy heparin history heparin induce thrombocytopenia History smoking use nicotinecontaining substance within previous 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Metformin</keyword>
	<keyword>INVOKANA®</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>